SynthesisFrontiers in endocrinology2026
The diagnosis and management of ectopic thyroid cancer: a systematic review.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ectopic thyroid carcinoma (ETC) is a rare malignancy for which standardized treatment guidelines remain unavailable. This systematic review aimed to comprehensively characterize the clinical features, treatment patterns, outcomes, and prognostic factors of ETC using the largest case-based dataset reported to date. Methods: A systematic literature search of PubMed, Scopus, and Web of Science was conducted from database inception to May 27, 2025. A total of 348 eligible reports were included. Data from 506 patients with ETC were extracted and analyzed, including demographics, tumor pathology, treatment strategies, recurrence, and survival outcomes. Results: The study included 506 patients, with a female-to-male ratio of 1.7:1 and a mean age of 41.6 years. Papillary thyroid carcinoma was the predominant histological subtype, accounting for 85.6% of cases. Most patients presented with localized disease (77.9%). Surgery was the primary treatment method (98.8%), and 40.6% of patients also received radioiodine therapy. Multivariable Cox regression showed that age >50 years (HR = 3.75, 95% CI: 1.92-7.32, P < 0.001) and ectopic tumor location in the chest, abdomen, or pelvis (HR = 7.23, 95% CI: 2.61-20.04, P < 0.001) were independently associated with worse overall survival. In the propensity-score-matched cohort, recurrence occurred in 3 of 50 patients who underwent orthotopic thyroidectomy and in 2 of 50 patients who did not, corresponding to recurrence rates of 6.0% and 4.0%, respectively. This difference was not statistically significant in paired analysis (McNemar P = 1.000). Conclusions: This systematic review provides the largest synthesis of ETC cases to date and identifies advanced age and non-cervical ectopic tumor location as adverse prognostic factors. Orthotopic thyroidectomy was not associated with reduced recurrence after propensity-score matching. However, given the small number of recurrence events and the case-based nature of the available evidence, this finding should be interpreted as hypothesis-generating rather than definitive. These results support a risk-adapted management strategy in which thyroidectomy is individualized rather than performed routinely. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420250630606.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.